Emerging biomarkers for acute heart conditions

Current Opinion in Cardiology

Volumn 29, Issue 4, 2014, Pages 312-318

  Vasile, Vlad C ^a   Jaffe, Allan S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute coronary syndromes; Copeptin; Galectin 3; Heart failure; ST2

Indexed keywords

COPEPTIN; GALECTIN 3; INTERLEUKIN 1 RECEPTOR; ST 2 PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; GALECTIN-3, HUMAN; GLYCOPEPTIDE; IL1RL1 PROTEIN, HUMAN; PROTEIN PRECURSOR;

ACUTE HEART FAILURE; DISEASE SEVERITY; HUMAN; PRIORITY JOURNAL; REVIEW; EARLY DIAGNOSIS; HEART FAILURE; MYOCARDIAL INFARCTION; RISK ASSESSMENT;

BIOLOGICAL MARKERS; EARLY DIAGNOSIS; GALECTIN 3; GLYCOPEPTIDES; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; PROTEIN PRECURSORS; RECEPTORS, CELL SURFACE; RISK ASSESSMENT;

EID: 84904814397     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000077     Document Type: Review

References (111)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
2. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-2195.
3. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-2538.
4. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-2653.
5. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-e140. Current guidelines for the diagnosis of myocardial infarction, which include biomarkers.
6. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:485-510. Current guidelines for the diagnosis of myocardial infarction, which include biomarkers.
7. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation; 127:e362-e425.
8. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-1604.
9. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111:570-575.
10. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-1792.
11. Sangiorgi G, Trimarchi S, Mauriello A, et al. Plasma levels of metalloproteinases-9 and -2 in the acute and subacute phases of type A and type B aortic dissection. J Cardiovasc Med (Hagerstown) 2006;7:307-315.
12. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139-1147.
13. Ray KK, Morrow DA, Gibson CM, et al. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J 2005;26:440-446.
14. Rallidis LS, Gika HI, Zolindaki MG, et al. Usefulness of elevated levels of soluble vascular cell adhesion molecule-1 in predicting in-hospital prognosis in patients with unstable angina pectoris. Am J Cardiol 2003;92:1195-1197.
15. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-1111.
16. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-1445.
17. Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004;291:435-441.
18. McCarthy ML. Overcrowding in emergency departments and adverse outcomes. BMJ 2011;342:d2830.
19. Lippi G, Cervellin G, Plebani M. Sensitive cardiac troponin T assay. N Engl J Med 2010;362:1242-1243.
20. Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem 2009;55:1303-1306.
21. Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009;54:1165-1172.
22. Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a highsensitivity cardiac troponin T assay. Clin Chem 2010;56:254-261.
23. De Lemos JA, Morrow DA, de Filippi CR. Highly sensitive troponin assays and the cardiology community: a love/hate relationship? Clin Chem 2011;57:826-829.
24. Collinson PO, Heung YM, Gaze D, et al. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin Chem 2012;58:219-225.
25. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-867.
26. Januzzi JL Jr, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J 2012;33:2265-2271.
27. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-2416.
28. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006;1760:616-635.
29. Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004;9:305-328.
30. Hrynchyshyn N, Jourdain P, Desnos M, et al. Galectin-3. A new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis 2013;106:541-546.
31. Michels VV, Moll PP, Miller FA, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992;326:77-82.
32. Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald's heart disease. A textbook of cardiovascular medicine. 9th ed. Philadelphia: Elsevier Science; 2011.
33. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-3128.
34. De Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11:811-817.
35. Liu YH, D'Ambrosio M, Liao TD, et al. N-acetyl-seryl-aspartyl-lysyl- proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009;296:H404-H412.
36. Christenson RH, Duh SH, Wu AH, et al. Multicenter determination of galectin-3 assay performance characteristics. Anatomy of a novel assay for use in heart failure. Clin Biochem 2010;43:683-690.
37. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60:1249-1256.
38. Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J 2013;165:995-999.
39. De Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272:55-64. Part of the PREVEND remodeling trial. It shows that galectin-3 is associated with age and risk factors of cardiovascular disease, with a strong sex interaction for these correlations. Galectin-3 predicted all-cause mortality in this cohort.
40. Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE ITTIMI 22. Clin Chem 2012;58:267-273.
41. Van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-1224.
42. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010;12:826-832.
43. De Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60-68.
44. Lok DJ, Van der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323-328.
45. Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012;5:72-78. Galectin-3 was significantly predictive of long-term outcomes, but this association did not persist after adjustment for other predictors, especially NT-proBNP.
46. Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011;108:385-390.
47. Sharma U, Rhaleb NE, Pokharel S, et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol 2008;294:H1226-H1232.
48. Gullestad L, Ueland T, Kjekshus J, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2012;33:2290-2296.
49. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 2011;12:200-210.
50. McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002;39:60-69.
51. Michelsen KS, Doherty TM, Shah PK, Arditi M. TLR signaling. An emerging bridge from innate immunity to atherogenesis. J Immunol 2004;173:5901-5907.
52. Abreu MT, Arditi M. Innate immunity and Toll-like receptors: clinical implications of basic science research. J Pediatr 2004;144:421-429.
53. 4+ T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. J Immunol 2001;166:3143-3150.
54. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164:277-281.
55. Leung BP, Xu D, Culshaw S, et al. A novel therapy of murine collageninduced arthritis with soluble T1/ST2. J Immunol 2004;173:145-150.
56. Kuroiwa K, Arai T, Okazaki H, et al. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001;284:1104-1108.
57. Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004;30:1468-1473.
58. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827-840.
59. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-1549.
60. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-954.
61. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family 8member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50:607-613.
62. Shah KB, Kop WJ, Christenson RH, et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem 2011;57:874-882.
63. Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009;54:2174-2179.
64. Bayes-Genis A, Pascual-Figal D, Januzzi JL, et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol 2010;63:1171-1178.
65. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
66. Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010;55:243-250.
67. Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure. Circ Heart Fail 2013;6:1206-1213.
68. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-2966.
69. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-2190.
70. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189.
71. Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936-1944.
72. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008;52:1458-1465.
73. Eggers KM, Armstrong PW, Califf RM, et al. ST2 and mortality in non-STsegment elevation acute coronary syndrome. Am Heart J 2010;159:788-794.
74. Kohli P, Bonaca MP, Kakkar R, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012;58:257-266.
75. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012;126:1596-1604. A multiple biomarker approach of cardiovascular stress detectable in ambulatory individuals added prognostic value to the standard risk factors for predicting death, overall cardiovascular events and heart failure.
76. Morgenthaler NG. Copeptin a biomarker of cardiovascular and renal function. Congest Heart Fail 2010;16(Suppl. 1):S37-S44.
77. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004;30:1276-1291.
78. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-119.
79. Katan M, Morgenthaler NG, Dixit KC, et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 2007;92:2640-2643.
80. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003;107:2313-2319.
81. Morgenthaler NG, Muller B, Struck J, et al. Copeptin a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219-226.
82. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005;26:2500-2504.
83. Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010;140:w13101.
84. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006;91:4381-4386.
85. De Marchis GM, Katan M, Weck A, et al. Copeptin and risk stratification in patients with ischemic stroke and transient ischemic attack: the CoRisk study. Int J Stroke 2013;8:214-218.
86. Kleindienst A, Brabant G, Morgenthaler NG, et al. Following brain trauma, copeptin, a stable peptide derived from the AVP precusor, does not reflect osmoregulation but correlates with injury severity. Acta Neurochir Suppl 2010;106:221-224.
87. Zweifel C, Katan M, Schuetz P, et al. Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol 2010;10:34.
88. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007;115:2103-2110.
89. Giannitsis E, Kehayova T, Vafaie M, Katus HA. Combined testing of highsensitivity troponin T and copeptin on presentation at prespecified cutoffs improves rapid rule-out of non-ST-segment elevation myocardial infarction. Clin Chem 2011;57:1452-1455.
90. Lotze U, Lemm H, Heyer A, Muller K. Combined determination of highly sensitive troponin T and copeptin for early exclusion of acute myocardial infarction: first experience in an emergency department of a general hospital. Vasc Health Risk Manag 2011;7:509-515.
91. Ray P, Charpentier S, Chenevier-Gobeaux C, et al. Combined copeptin and troponin to rule out myocardial infarction in patients with chest pain and a history of coronary artery disease. Am J Emerg Med 2012;30:440-448. For patients with acute chest pain lasting for less than 6 h and a previous history of CAD, the combination of a normal copeptin and normal cTn allows for ruling out AMI, with a negative predictive value greater than 95%.
92. Karakas M, Januzzi JL Jr, Meyer J, et al. Copeptin does not add diagnostic information to high-sensitivity troponin T in low- to intermediate-risk patients with acute chest pain: results from the rule out myocardial infarction by computed tomography (ROMICAT) study. Clin Chem 2011;57:1137-1145.
93. Bhandari SS, Loke I, Davies JE, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009;116:257-263.
94. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009;54:60-68.
95. Melanson SE, Morrow DA, Jarolim P. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol 2007;128:282-286.
96. Peacock WF. Will SCUBE1 solve the ischemia marker deficit? J Am Coll Cardiol 2008;51:2181-2183.
97. Gu YL, Voors AA, Zijlstra F, et al. Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin Res Cardiol 2011;100:1069-1076.
98. Dhillon OS, Khan SQ, Narayan HK, et al. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-STelevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J Am Coll Cardiol 2010;56:125-133.
99. Moeckel M, Giannitsis E, Blankenberg S, et al. BIC-8. Instant early rule-out using cardiac troponin and copeptin in low- to intermediate-risk patients with suspected ACS: a prospective, randomized multicenter study. Amsterdam: European Society of Cardiology; 2013. Study argues that instant early rule-out using both cardiac troponin and copeptin in low- to intermediate-risk patients with suspected acute coronary syndromes presenting to the emergency department was safe for patients to be discharged home.
100. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-1729.
101. Kelly D, Squire IB, Khan SQ, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 2008;14:739-745.
102. Goldsmith SR, Francis GS, Cowley AW Jr, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;1:1385-1390.
103. Szatalowicz VL, Arnold PE, Chaimovitz C, et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-266.
104. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 2005;95:8B-13B.
105. Holmes CL. Vasopressin in septic shock: does dose matter? Crit Care Med 2004;32:1423-1424.
106. Abraham WT, Shamshirsaz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, nonpeptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006;47:1615-1621.
107. Serradeil-Le Gal C, Wagnon J, Valette G, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog. Brain Res 2002;139:197-210.
108. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-1331.
109. Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006;36:771-778.
110. Maisel A, Xue Y, Shah K, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail 2011;4:613-620.
111. Miller WL, Hartman KA, Hodge DO, et al. Response of novel biomarkers to BNP infusion in patients with decompensated heart failure: a multimarker paradigm. J Cardiovasc Transl Res 2009;2:526-535.